IntelGenx shared the decision placed by the Delaware Court in which the process used to manufacture an opiate addiction treatment does not infringe the patent of MonoSol Rx.

IntelGenx (TSXV:IGX; OTCQX:IGXT) shared the decision placed by the Delaware Court in which the process used to manufacture an opiate addiction treatment does not infringe the patent of MonoSol Rx.
As quoted in the press release:

“This is a great outcome for IntelGenx, confirming that our process for making generic Suboxone® film does not infringe the process covered by the ‘497 patent’,” said Dr. Horst G. Zerbe, President and CEO of IntelGenx.
Also on August 31, 2017, the Delaware Court rendered a decision in a separate case, which previously resulted in a finding infringement of the MonoSol Rx U.S. Patent No 8,603,514 (the “514 patent”), denying IntelGenx’ and Par’s motion to reopen the case.
Dr. Zerbe further commented, “According to IMS data, the oral film market for opioid dependence in the United States was worth more than $1.4 billion in 2014. We are working with Par on the appeal process.”

Click here to read the full press release.

Source: www.marketwired.com

addiction generic intelgenx opioid dependence patent suboxone united states Pharmaceutical Investing